Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Docetaxel, and Bevacizumab vs Placebo in Uterine Leiomyosarcoma
NCT01012297Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2009
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in uterine leiomyosarcoma (uLMS), sponsored by National Cancer Institute. Started Nov 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT01012297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012297.